Sign up to save your podcasts
Or
Share Taking Action Against RSV: No Child Unprotected
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Taking Action Against RSV: No Child Unprotected
CME credits: 0.50
Valid until: 04-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/taking-action-against-rsv-no-child-unprotected/39307/
This three-part educational activity reviews the burden of respiratory syncytial virus (RSV) and evidence-based strategies to prevent disease in infants and young children. Chapter 1 examines the epidemiology of RSV and outlines current prophylactic options, including maternal vaccination and the monoclonal antibodies nirsevimab (approved 2023) and clesrovimab (approved 2025). Chapter 2 summarizes American Academy of Pediatrics (AAP) recommendations with guidance on timing, maternal vaccination status, coadministration, and the importance of hospital-based immunization for newborns. Chapter 3 focuses on effective parent–clinician communication, emphasizing shared decision-making, addressing concerns and misinformation, and supporting timely immunization to reduce RSV-related morbidity and mortality.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.50
Valid until: 04-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/taking-action-against-rsv-no-child-unprotected/39307/
This three-part educational activity reviews the burden of respiratory syncytial virus (RSV) and evidence-based strategies to prevent disease in infants and young children. Chapter 1 examines the epidemiology of RSV and outlines current prophylactic options, including maternal vaccination and the monoclonal antibodies nirsevimab (approved 2023) and clesrovimab (approved 2025). Chapter 2 summarizes American Academy of Pediatrics (AAP) recommendations with guidance on timing, maternal vaccination status, coadministration, and the importance of hospital-based immunization for newborns. Chapter 3 focuses on effective parent–clinician communication, emphasizing shared decision-making, addressing concerns and misinformation, and supporting timely immunization to reduce RSV-related morbidity and mortality.
=